Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARTL Artelo Biosciences Inc

-0.03 (-2.07%)
Last Updated: 11:51:35
Delayed by 15 minutes


Draw Mode:

Volume 2,834
Bid Price 1.41
Ask Price 1.45
News -
Day High 1.45


52 Week Range


Day Low 1.39
Company Name Stock Ticker Symbol Market Type
Artelo Biosciences Inc ARTL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.03 -2.07% 1.42 11:51:35
Open Price Low Price High Price Close Price Prev Close
1.39 1.39 1.45 1.45
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
23 2,834 $ 1.42 $ 4,025 - 1.15 - 3.50
Last Trade Time Type Quantity Stock Price Currency
11:42:28 1 $ 1.4373 USD

Artelo Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.53M 3.19M - 0 -10.08M -3.16 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Artelo Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ARTL Message Board. Create One! See More Posts on ARTL Message Board See More Message Board Posts

Historical ARTL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.461.531.351.4316,303-0.04-2.74%
1 Month1.421.531.151.3120,8410.000.0%
3 Months1.521.781.151.4530,684-0.10-6.58%
6 Months1.942.981.151.86142,307-0.52-26.8%
1 Year2.533.501.151.9581,940-1.11-43.87%
3 Years0.627.200.25991.471,793,0090.80129.03%
5 Years4.957.200.25991.421,365,964-3.53-71.31%

Artelo Biosciences Description

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Your Recent History

Delayed Upgrade Clock